Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers (TOG/GI-SAFRADJU-2501)
NCT ID: NCT06975917
Last Updated: 2025-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
600 participants
OBSERVATIONAL
2024-11-01
2025-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Are any of the chemotherapy regimens more effective in preventing recurrence, providing longer survival, or having less toxicity?
Nationwide multicenter retrospective data will be collected.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer
NCT05451290
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
NCT03257761
Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
NCT00626158
Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients
NCT00301379
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient with biliary tract cancer
Patients with biliary tract cancer, who underwent resection and received adjuvant chemotherapy
Chemotherapy
Any chemotherapy regimen that is used in the adjuvant setting
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Chemotherapy
Any chemotherapy regimen that is used in the adjuvant setting
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Underwent curative-intent resection
Exclusion Criteria
* Ampullary cancers
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Turkish Oncology Group
NETWORK
Ankara University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Erman Akkus
Principle Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ankara University Faculty of Medicine Department of Medical Oncology
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
i09-714-24
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.